Injectable nanorobots fused with stem cells show promise for spinal cord injury repair
By
Andrew Paul
Summary
Researchers at ETH Zurich have developed injectable nanorobots fused with stem cells that respond to electromagnetic signals, showing promise in helping heal spinal cord injuries. In zebrafish studies, the microrobots enabled nerve cell growth after spinal cord injury, addressing the key challenges of scarring that blocks nerve fiber regrowth and the inability of nerve cells to regenerate on their own.
Source
Key quotes
· 2 pulledDespite significant medical advances, spinal cord damage remains one of the most difficult physical injuries to treat.
Scarring frequently gets in the way of nerve fiber regrowth, while nerve cells usually cannot regenerate on their own.
You might also wanna read

Polylaminin polymer improves motor function recovery after spinal cord injury in rat model
This study investigates the use of polylaminin, a biomimetic polymer form of laminin, for treating spinal cord injury (SCI) in rats. While l
Brazilian Researchers Develop Polylaminin Drug That May Reverse Spinal Cord Injuries
Brazilian researchers have developed a groundbreaking drug called polylaminin, derived from placental protein laminin, that shows promise in
Texas A&M study shows mammals may have hidden regenerative abilities that could be activated
New research from Texas A&M University suggests that mammals, including humans, may possess hidden regenerative abilities that are normally
Fusogenic neurosurgery helps paralyzed pigs walk again, but human trials face significant hurdles
A new surgical technique called 'fusogenic neurosurgery' has allowed pigs with completely severed spinal cords to walk again, performed by a
Nature research paper: Confined migration induces non-lethal DNA damage in developing neurons
Researchers Study Axolotls for Limb Regeneration Insights
Researchers are using gene-edited axolotls to understand limb regeneration, potentially aiding human limb regrowth.
Comments
Sign in to join the conversation.
No comments yet. Be the first.
